Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug.
Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.
Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardior Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.
By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
Covera Health has finalized its acquisition of CoRead, the companies announced last week but did not disclose the terms of the deal. Covera also announced that it raised up to $50 million in additional Series C funding led by Insight Partners.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
Abcam’s acquisition comes two months after its board announced the exploration of strategic alternatives that could include the sale of the company. Danaher beat out at least 20 companies that were potential buyers of the life sciences tools and antibody development firm.
Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition. The deal with Novartis also includes two experimental products, one for eye pain and the other a medical device for delivering medicines to the eye.
Through Maven's acquisition, Naytal’s over 50 providers will join Maven’s platform, more than doubling the company’s number of providers in the U.K. Maven will also be able to sign on additional U.K.-based clients.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
The $100 million deal between Transcarent and 98point6 is expected to close March 31 and is a combination of equity and cash, said Glen Tullman, CEO of Transcarent. Through the acquisition, Transcarent will gain access to 98point6’s AI-powered text-based technology, affiliated provider group and client base.
By adding 450 primary care practices to its network, the company claims to be the largest network of independent primary care. In total, the company now works with more than 1,500 independent primary care practices and health centers and has more than 150 value-based contracts across Medicare, Medicare Advantage, Medicaid and commercial plans.
Elation Health announced its acquisition of medical billing company Lightning MD — a deal the company made to help it become an all-in-one technology platform for primary care providers. Lightning MD stood out from other medical billing startups because of its ease of use, Elation CEO Kyna Fong said.
About 73% of health insurance markets are highly concentrated, and in 46% of markets, one insurer had a share of 50% or more, a new report from the American Medical Association shows. The report comes a few months after President Joe Biden directed federal agencies to ramp up oversight of healthcare consolidation.
Which capital funding options fit your healthcare or life science business?